Ignite Creation Date:
2025-12-25 @ 12:30 AM
Ignite Modification Date:
2026-01-22 @ 8:15 AM
Study NCT ID:
NCT03833167
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-24
First Post:
2019-02-04
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-04-01
Start Date Type:
ACTUAL
Primary Completion Date:
2024-06-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-01-19
Completion Date Type:
ESTIMATED
First Submit Date:
2019-02-04
First Submit QC Date:
None
Study First Post Date:
2019-02-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-06-17
Results First Submit QC Date:
None
Results First Post Date:
2025-07-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-05
Last Update Post Date:
2025-12-24
Last Update Post Date Type:
ACTUAL